Taken together, our data reveal a novel molecular mechanism that operates in BCR–ABL1-induced tumorigenesis that can be used to develop new strategies to help TKI-resistant, CML patients in blast crisis (BC). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.